What is the recommended treatment and dosage of Elobixibat for constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Elobixibat for Chronic Constipation

Recommended Dosage

Elobixibat should be administered at 10 mg once daily before breakfast for the treatment of chronic constipation. 1

  • The 10 mg dose was identified as the clinically optimal dose in phase II dose-finding studies, where it significantly increased spontaneous bowel movements to 6.4 per week compared to 2.6 per week with placebo 2, 3
  • Patients may titrate between 5 mg, 10 mg, or 15 mg daily based on response and tolerability, though 10 mg represents the standard starting dose 3
  • The medication must be taken before breakfast, as food consumption reduces systemic exposure by approximately 80% while paradoxically increasing the therapeutic effect 4

Clinical Role in Treatment Algorithm

The American Gastroenterological Association recommends elobixibat as a second-line therapy for chronic idiopathic constipation when first-line treatments (such as polyethylene glycol or other osmotic laxatives) provide inadequate relief. 1

  • Elobixibat is equally effective in patients with or without constipation-predominant irritable bowel syndrome, making it versatile across constipation phenotypes 1, 2
  • The drug works through a unique mechanism as an ileal bile acid transporter inhibitor, increasing bile acid delivery to the colon to stimulate both colonic motility and secretion 5

Efficacy Timeline

  • Therapeutic effects begin during the first week of treatment, with the primary endpoint showing significant improvement in spontaneous bowel movement frequency by week 1 3
  • Long-term efficacy is maintained through 52 weeks of continuous treatment without tachyphylaxis 3, 6

Safety Profile and Common Pitfalls

The most frequent adverse effects are mild gastrointestinal symptoms that are dose-dependent: abdominal pain occurs in 19-24% of patients and diarrhea in 13-15%. 1, 3

  • In the 52-week safety study, 48% of patients experienced adverse drug reactions, predominantly mild gastrointestinal disorders, with no serious adverse events directly attributed to elobixibat 1, 3
  • Critical administration error to avoid: Patients must take elobixibat before breakfast on an empty stomach; taking it with food dramatically reduces absorption while increasing bile acid effects, potentially worsening gastrointestinal side effects 4
  • If gastrointestinal side effects occur, dose reduction to 5 mg daily is appropriate before discontinuation 3

Additional Metabolic Benefits

  • Elobixibat reduces LDL cholesterol levels and increases serum GLP-1, providing potential cardiovascular and metabolic benefits beyond constipation relief 5, 4
  • The drug is minimally absorbed systemically, with a potential slight inhibitory effect on P-glycoprotein that is clinically insignificant 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.